UK Renal Registry, Southmead Hospital, Bristol, UK.
Nephron Clin Pract. 2011;119 Suppl 2:c149-77. doi: 10.1159/000331759. Epub 2011 Aug 26.
The UK Renal Association (RA) and National Institute for Health and Clinical Excellence (NICE) have published Clinical Practice Guidelines which include recommendations for management of anaemia in established renal failure.
To determine the extent to which the guidelines for anaemia management are met in the UK.
Quarterly data were obtained regarding haemoglobin (Hb) and factors that influence Hb from renal centres in England, Wales, Northern Ireland (EWNI) and the Scottish Renal Registry for the incident and prevalent renal replacement therapy (RRT) cohorts for 2009.
In the UK, in 2009 55% of patients commenced dialysis therapy with Hb x10.0 g/dl (median Hb 10.2 g/dl). The median Hb of haemodialysis (HD) patients was 11.6 g/dl with an interquartile range (IQR) of 10.6 - 12.4 g/dl. Of HD patients 85% had Hb ≥ 10.0 g/dl. The median Hb of peritoneal dialysis (PD) patients in the UK was 11.7 g/dl (IQR 10.7-12.6 g/dl). Of UK PD patients, 88% had Hb ≥ 10.0 g/dl. The median ferritin in HD patients in EWNI was 441 mg/L (IQR 289-629) and 96% of HD patients had a ferritin ≥ 100 mg/L. The median ferritin in PD patients was 249 mg/L (IQR 142-412) with 86% of PD patients having a ferritin 5100 mg/L. In EWNI the mean Erythropoietin Stimulating Agent (ESA) dose was higher for HD than PD patients (9,507 vs. 6,212 IU/week).
In 2009, 56% of prevalent HD patients had a Hb ≥ 10.5 and ≤ 12.5 g/dl compared with 54% in 2008 and 53% in 2007. Fifty-four percent of prevalent PD patients had a Hb ≥10.5 and ≤12.5 g/dl compared to 55% in 2008.
英国肾脏协会（RA）和国家卫生与临床优化研究所（NICE）发布了临床实践指南，其中包括对已确诊肾衰竭患者贫血管理的建议。
确定英国在贫血管理指南方面的实施程度。
2009 年，从英格兰、威尔士、北爱尔兰（EWNI）和苏格兰肾脏登记处的肾脏中心定期获得血红蛋白（Hb）和影响 Hb 的因素的数据，这些数据来自新开始血液透析治疗和持续性血液透析治疗的患者队列。
2009 年，英国有 55%的血液透析治疗患者开始透析治疗时 Hb 为 x10.0 g/dl（中位数 Hb 为 10.2 g/dl）。血液透析（HD）患者的中位数 Hb 为 11.6 g/dl，四分位间距（IQR）为 10.6-12.4 g/dl。85%的 HD 患者 Hb ≥ 10.0 g/dl。英国腹膜透析（PD）患者的中位数 Hb 为 11.7 g/dl（IQR 10.7-12.6 g/dl）。88%的英国 PD 患者 Hb ≥ 10.0 g/dl。EWNI 中 HD 患者的中位数铁蛋白为 441 mg/L（IQR 289-629），96%的 HD 患者铁蛋白≥100 mg/L。PD 患者的中位数铁蛋白为 249 mg/L（IQR 142-412），86%的 PD 患者铁蛋白为 5100 mg/L。在 EWNI，HD 患者的平均红细胞生成素刺激剂（ESA）剂量高于 PD 患者（9507 vs. 6212 IU/周）。
2009 年，与 2008 年的 54%和 2007 年的 53%相比，56%的持续性 HD 患者 Hb≥10.5 和≤12.5 g/dl。与 2008 年的 55%相比，54%的持续性 PD 患者 Hb≥10.5 和≤12.5 g/dl。
